Q-POC

Target SDGs

Market Suggested Retail Price

$1,000.00

Target Users (Target Impact Group)

Small and Medium-sized Enterprises, Public Sector Agencies, NGOs

Distributors / Implementing Organizations

Currently unknown, but QuantuMDx is partnered with several NGOs, including FIND, the Bill and Melinda Gates Foundation, the Clinton Foundation, and the Global Good Fund.

Regions

Africa, Asia

Manufacturing/Building Method

QuantuMDx has partnered with Integrated Technologies Ltd. to manufacture batches of prototypes and eventually mass produce the final product.

Intellectural Property Type

Patent

User Provision Model

Unknown, as the product has not been commercialized yet.

Distributions to Date Status

N/A, product commercialization expected 2019

Design Specifications

The Q-POC is a portable, battery-operated diagnostics device that can process blood, urine, sputum, tissue, and swabs and delivers results in 10-20 minutes.

Results are displayed on a touchscreen and can be stored on the device, sent to a printer, or transferred to a computer or the Cloud via USB or WiFi.

Globally distributed Q-POC devices will also geotag and anonymize pathogen data and send to the cloud for real-time disease and drug resistance monitoring.

[caption id="attachment_63588" align="alignnone" width="400"] Technical Specifications of Q-POC[/caption]

Product Schematics

Technical Support

Provided by the manufacturer

Replacement Components

Testing cassettes

Lifecycle

Unknown

Manufacturer Specified Performance Parameters

QuantuMDx seeks Q-POC can provide personalized medicine, be portable, provide a quick diagnosis, allow for geotagging an creating a network of data.

Vetted Performance Status

99% sensitivity and specificity to molecular results were claimed.

Safety

Unknown

Complementary Technical Systems

None

Academic Research and References

Compliance with regulations

QuantumDx plans to obtain CE marking for all of the Q-POC tests in the short term and then pursue a 510(k) submission with the US Food and Drug Administration.

Evaluation methods

Clinical trials planned in South Africa, sensitivity tests performed.

Other Information

None